| |
A20E10 (n = 48)
|
A40 (n = 50)
|
P value
|
|---|
|
ALT(U/L)
|
|
Baseline
|
23.44 ± 15.36
|
19.90 ± 10.84
|
0.190
|
|
Week 4
|
30.20 ± 14.52
|
27.51 ± 16.78
|
0.410
|
|
Week 12
|
31.39 ± 19.38
|
28.39 ± 22.36
|
0.552
|
|
AST(U/L)
|
|
Baseline
|
19.89 ± 5.99
|
17.80 ± 6.01
|
0.089
|
|
Week 4
|
22.84 ± 5.69
|
21.24 ± 6.92
|
0.231
|
|
Week 12
|
31.39 ± 19.38
|
28.39 ± 22.36
|
0.321
|
|
CK(U/L)
|
|
Baseline
|
82.13 ± 35.11
|
107.60 ± 117.44
|
0.157
|
|
Week 4
|
95.05 ± 35.58
|
100.86 ± 40.46
|
0.466
|
|
Week 12
|
104.39 ± 48.86
|
115.60 ± 57.01
|
0.386
|
- Notes: A20E10 indicates the patients who received Atorvastatin 20 mg qn plus Ezetimibe 10 mg qd,A40 indicates the patients who received Atorvastatin 40 mg qn
